Fuente: PubMed "hive" Arch Bronconeumol. 2026 Apr 24:S0300-2896(26)00150-X. doi: 10.1016/j.arbres.2026.04.008. Online ahead of print.ABSTRACTT2-comorbidities including allergic rhinitis, chronic rhinosinusitis with and without nasal polyps, atopic dermatitis, chronic spontaneous urticaria, food allergy, aspirin sensitivity and eosinophilic esophagitis are the most common in severe asthma (SA) patients and have a negative impact on disease outcomes but also an important socio-economic burden. In the era of personalized medicine, treating SA and its comorbidities by one medication is a very exciting possibility for the clinicians. Several biologics used for SA showed benefits on T2-comorbidities but current knowledge regarding the magnitude and consistency of biologics efficacy across these comorbidities as well as the optimal strategies for selecting biologics in multimorbid patients remain limited. In this narrative review, we discuss the available evidence on the efficacy and safety of different biologics currently available as add-on treatment for SA on the most frequent T2-comorbidities, individually or associated, based on randomized controlled trials and real-world studies.PMID:42106281 | DOI:10.1016/j.arbres.2026.04.008